JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Boston Scientific Corp.

Cerrado

SectorSanidad

101.13 -1.24

Resumen

Variación precio

24h

Actual

Mínimo

101.02

Máximo

101.42

Métricas clave

By Trading Economics

Ingresos

123M

795M

Ventas

398M

5.1B

P/B

Media del Sector

59.135

37.461

Margen de beneficios

15.708

Empleados

53,000

EBITDA

155M

1.4B

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+25.06% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-4.6B

149B

Apertura anterior

102.37

Cierre anterior

101.13

Noticias sobre sentimiento de mercado

By Acuity

30%

70%

68 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Boston Scientific Corp. Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

22 oct 2025, 11:00 UTC

Ganancias

Boston Scientific Raises Outlook on Continued Cardiovascular Growth

17 oct 2025, 11:43 UTC

Adquisiciones, fusiones, absorciones

Boston Scientific to Buy Rest of Nalu Medical for $533 Million

23 jul 2025, 11:16 UTC

Ganancias

Boston Sci 2Q Net Surges, Company Boosts '25 EPS View on Cardiology Demand

22 oct 2025, 10:32 UTC

Ganancias

Boston Scientific Sees 4Q Organic Sales Up 11%-13% >BSX

22 oct 2025, 10:32 UTC

Ganancias

Boston Scientific Sees 4Q Sales Up 14.5-16.5% >BSX

22 oct 2025, 10:31 UTC

Ganancias

Boston Scientific Sees 2025 Organic Sales Up About 15.5% >BSX

22 oct 2025, 10:31 UTC

Ganancias

Boston Scientific Sees 2025 Sales Up About 20% >BSX

22 oct 2025, 10:30 UTC

Ganancias

Boston Scientific Sees FY Adj EPS $3.02-Adj EPS $3.04 >BSX

22 oct 2025, 10:30 UTC

Ganancias

Boston Scientific 3Q Organic Sales Up 15.3% >BSX

22 oct 2025, 10:30 UTC

Ganancias

Boston Scientific 3Q Adj EPS 75c >BSX

22 oct 2025, 10:30 UTC

Ganancias

Boston Scientific Sees FY EPS $1.97-EPS $2.01 >BSX

22 oct 2025, 10:30 UTC

Ganancias

Boston Scientific Sees 4Q EPS 48c-EPS 52c >BSX

22 oct 2025, 10:30 UTC

Ganancias

Boston Scientific 3Q Sales $5.07B >BSX

22 oct 2025, 10:30 UTC

Ganancias

Boston Scientific 3Q EPS 51c >BSX

22 oct 2025, 10:30 UTC

Ganancias

Boston Scientific Sees 4Q Adj EPS 77c-Adj EPS 79c >BSX

17 oct 2025, 11:02 UTC

Adquisiciones, fusiones, absorciones

Boston Scientific to Make Upfront Cash Payment of About $533 Million for Nalu Equity it Doesn't Already Own >BSX

17 oct 2025, 11:02 UTC

Adquisiciones, fusiones, absorciones

Boston Scientific: Nalu Acquisition to Expand Neuromodulation Offerings for People Living With Chronic Pain >BSX

17 oct 2025, 11:01 UTC

Adquisiciones, fusiones, absorciones

Boston Scientific: Nalu Medical Focused on Developing Minimally Invasive Solutions for Chronic Pain >BSX

17 oct 2025, 11:00 UTC

Adquisiciones, fusiones, absorciones

Boston Scientific Announces Agreement To Acquire Nalu Medical, Inc. >BSX

9 sept 2025, 12:58 UTC

Adquisiciones, fusiones, absorciones

Boston Scientific to Buy Elutia's Bioenvelope Business for $88M

9 sept 2025, 12:31 UTC

Adquisiciones, fusiones, absorciones

Elutia Announces Sale of BioEnvelope Business to Boston Scientific for $88M

23 jul 2025, 10:32 UTC

Ganancias

Boston Scientific Sees 3Q Sales Up 17%-19%, Organic Sales Up 12%-14% >BSX

23 jul 2025, 10:31 UTC

Ganancias

Boston Scientific Sees 2025 Sales Up 18%-19%, Organic Sales Up 14%-15% >BSX

23 jul 2025, 10:30 UTC

Ganancias

Boston Scientific Sees FY EPS $1.89-EPS $1.93 >BSX

23 jul 2025, 10:30 UTC

Ganancias

Boston Scientific 2Q Organic Sales Up 17.4% >BSX

23 jul 2025, 10:30 UTC

Ganancias

Boston Scientific 2Q EPS 53c >BSX

23 jul 2025, 10:30 UTC

Ganancias

Boston Scientific 2Q Sales $5.06B >BSX

23 jul 2025, 10:30 UTC

Ganancias

Boston Scientific Sees 3Q Adj EPS 70c-Adj EPS 72c >BSX

23 jul 2025, 10:30 UTC

Ganancias

Boston Scientific 2Q Adj EPS 75c >BSX

23 jul 2025, 10:30 UTC

Ganancias

Boston Scientific Sees FY Adj EPS $2.95-Adj EPS $2.99 >BSX

Comparación entre iguales

Cambio de precio

Boston Scientific Corp. previsión

Precio Objetivo

By TipRanks

25.06% repunte

Estimación a 12 Meses

Media 126.45 USD  25.06%

Máximo 140 USD

Mínimo 113 USD

De acuerdo con 24 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Boston Scientific Corp. Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

24 ratings

23

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

102.95 / 104.93Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Weak Bearish Evidence

Largo Plazo

No Evidence

Sentimiento

By Acuity

68 / 371 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
help-icon Live chat